Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hematological malignancies with eosinophilia]

S Okamura1, W Ikematsu

  • 1Cancer Center, Kyushu University Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement of the Z-Boson Mass.

Physical review letters·2025
Same author

Observation of a New Charmed Baryon Decaying to Ξ_{c}^{+}π^{-}π^{+}.

Physical review letters·2025
Same author

Observation of the Very Rare Σ^{+}→pμ^{+}μ^{-} Decay.

Physical review letters·2025
Same author

Evidence for B^{-}→D^{**0}τ^{-}ν_{τ}[over ¯] Decays.

Physical review letters·2025
Same author

Test of Lepton Flavor Universality with B_{s}^{0}→ϕℓ^{+}ℓ^{-} Decays.

Physical review letters·2025
Same author

Observation of the Open-Charm Tetraquark Candidate T_{cs0}^{*}(2870)^{0} in the B^{-}→D^{-}D^{0}K_{S}^{0} Decay.

Physical review letters·2025
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Hematological malignancies with eosinophilia arise from neoplastic cells differentiating into eosinophils or from tumor cells secreting cytokines that stimulate eosinophil precursors. This review explores chromosomal changes and cytokine roles in these conditions.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Context:

  • Eosinophilia in hematological malignancies presents complex mechanisms.
  • Understanding these mechanisms is crucial for diagnosis and treatment.
  • Chromosomal abnormalities and cytokine dysregulation play significant roles.

Purpose:

  • To review the relationship between hematological malignancies, eosinophilia, chromosomal changes, and cytokine production.
  • To categorize the mechanisms driving eosinophilia in these cancers.
  • To highlight specific examples of malignancies and their associated genetic and molecular features.

Summary:

  • Hematological malignancies with eosinophilia are categorized into two groups: those where neoplastic cells differentiate into eosinophils (e.g., FAB M4Eo, FAB M2 t(8;21), CML) and those where tumor cells secrete eosinophil-stimulating cytokines (e.g., IL-3, IL-5, GM-CSF).

Related Experiment Videos

  • These cytokines stimulate normal eosinophil precursor proliferation in lymphoid malignancies like acute lymphoblastic leukemia (t(5;14)) and lymphomas (Hodgkin's, ATLL).
  • The review links specific chromosomal changes (e.g., t(8;21), t(5;14)) to these distinct pathogenic pathways.

    • Impact:

    • Provides a framework for understanding the diverse origins of eosinophilia in blood cancers.
    • Informs potential therapeutic strategies targeting cytokine pathways or specific neoplastic cell differentiation.
    • Enhances diagnostic accuracy by correlating specific malignancies with underlying genetic and molecular drivers.